Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 September 2021 | Story Leonie Bolleurs | Photo Sonia Small (Kaleidoscope Studios)
Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact, will be speaking at the International Summit on the Sustainable Development Goals (SDGs) in Africa 2021.

Dr Molapo Qhobela, the newly appointed Vice-Rector: Institutional Change, Strategic Partnerships and Societal Impact at the University of the Free State (UFS), will be speaking at the three-day International Summit on the Sustainable Development Goals (SDGs) in Africa 2021. The summit will take place as follows:

Date: 13-15 September 2021 
Platform: A virtual gathering (register for the upcoming virtual summit)

Together with a wide array of thought leaders, including specialists, senior researchers, CEOs/directors, and the top structures of international organisations, he will address and engage with an audience of academics, practitioners, government authorities, representatives from civil society, and donors and sponsors from across the globe on the topic Partnerships for impact in Africa (session on 15 September from 12:30 to 14:00).

According to the host of the event, the University of Cape Town, the key aim of the International Summit on the SDGs in Africa is to mobilise collaborative efforts that will accelerate African-led activities in support of achieving the African Union's Agenda 2063 and the United Nations Sustainable Development Goals (SDGs) – a shared blueprint for working towards global peace and prosperity by 2030. The summit is also designed to identify concrete opportunities for research collaboration that will accelerate the achievement of the SDGs and Agenda 2063.

The talks, panel discussions, workshops, and breakout sessions will revolve around clear steps for implementation.

For more information, visit: http://www.sdgsafricasummit.uct.ac.za/

Background of Dr Molapo Qhobela

Dr Qhobela’s leadership and strategic direction have been sought by several large and complex organisations during his career. He is the immediate former Chief Executive Officer (CEO) of the National Research Foundation, and also the former Chair of the Global Research Council as well as the Agricultural Research Council. He is currently the Chairperson of the Tertiary Education and Research Network of South Africa. Dr Qhobela holds a PhD in Plant Pathology from the Kansas State University in the United States of America.

News Archive

Researchers receive study grant for research into Congo Fever
2015-03-10

UFS researchers will be contributing significantly to the search for a vaccine against the deadly tick-borne disease known as Congo Fever.

Prof Felicity Burt from the Department of Medical Microbiology and Virology was recently awarded a research grant by the National Health Laboratory Service (NHLS) to study candidate vaccines for Crimean-Congo heamorrhagic fever (CCHF) virus and other arboviruses.

Arboviruses are viruses transmitted by mosquitoes, ticks, or other arthropods.

Prof Burt is an internationally-recognised expert on the Crimean-Congo haemorrhagic fever (CCHF). The Crimean-Congo haemorrhagic fever (CCHF) virus is a tick-borne virus that is associated with severe haemorrhagic disease in South Africa and other parts of Africa, Asia, and eastern Europe. Her interests focus on medically significant viruses that are transmitted by ticks and mosquitoes. Her research group is involved in determining the immune responses that are induced by different viral proteins.

Crimean-Congo haemorrhagic fever (CCHF) virus, a tick- borne virus found in Africa, Asia, the Balkans, and eastern Europe, causes severe viral haemorrhagic fever outbreaks.

Although a number of tick species are capable of becoming infected with CCHF virus, ticks of the genus Hyalomma, commonly referred to in SA as the “bont-legged ticks”, are the principal vector. The ticks have distinctive brown and white bands on their legs.

In February 1981, the first case of CCHF was recognised in South Africa (SA). To date, there have been nearly 200 cases of CCHF infection in SA with a 20% fatality rate. The majority of cases occurring in SA were in patients from the Northern Cape and Free State provinces.

“The funding that has been awarded will be used to profile immune responses against CCHF viral proteins, and investigate mechanisms and strategies to enhance these immune responses. We hope that the study will contribute knowledge towards the development of a vaccine against this medically significant virus.”

For more information or enquiries contact news@ufs.ac.za.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept